Biosimilar Contract Manufacturing Market Report 2026

The biosimilar contract manufacturing market size has grown rapidly in recent years. It will grow from $9.94 billion in 2025 to $11.49 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to expiration of reference biologic patents, early adoption of biosimilar development programs, expansion of contract manufacturing partnerships, increasing regulatory guidance on biosimilars, growth in chronic disease prevalence.

The biosimilar contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $20.35 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing biosimilar approvals across global markets, rising pressure to reduce biologic treatment costs, expansion of biosimilar pipelines, growing investments in large-scale manufacturing capacity, advancements in process optimization technologies. Major trends in the forecast period include increasing outsourcing of biosimilar manufacturing, rising demand for cost-efficient production platforms, growing focus on analytical and quality control services, expansion of mammalian cell-based manufacturing, enhanced emphasis on regulatory compliance.

The increasing prevalence of diabetes is anticipated to drive expansion in the biosimilar contract manufacturing market. Diabetes prevalence measures the share of a population affected by diabetes at any given time, indicating sustained demand for lifelong treatments. This surge stems from rising sedentary behaviors and unhealthy eating patterns, which contribute to obesity, insulin resistance, and elevated rates of type 2 diabetes. Biosimilar contract manufacturing aids diabetes care by facilitating scalable, affordable production of biosimilar insulins and associated biologics. It guarantees reliable quality and adherence to regulations, thereby broadening access to sophisticated therapies for patients. This boosts affordability and expands worldwide availability of vital diabetes treatments. For instance, in June 2024, the National Health Service - a UK government entity - reported that 3,615,330 people registered with general practitioners had non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 cases the previous year. Thus, the rising diabetes prevalence is fueling growth in the biosimilar contract manufacturing market.

Major companies in the biosimilar contract manufacturing market are prioritizing the development of production facilities like mirrored single-use plants to speed up tech transfer, scale-up, and commercial reliability. These mirrored single-use plants feature identical production suites equipped with disposable bioprocess equipment and unified digital systems, which support quick changeovers, uniform quality across locations, and reduced contamination risks. For example, in September 2025, Rezon Bio - a Poland-based contract development and manufacturing organization (CDMO) - opened two mirrored-capability single-use biomanufacturing sites that span cell line development to commercial GMP supply. This strategy facilitates faster technology transfer and adaptable scale-up for biosimilars with minimal downtime, while enhancing batch-to-batch consistency via standardized suites, integrated analytics, and logistics automation. It also reduces the total cost of ownership for sponsors by cutting cleaning validation needs, accelerating development and manufacturing timelines, and mitigating expansion risks.

In October 2023, Advent International Corporation, a US-based private equity firm, and Warburg Pincus LLC, another US-based private equity firm, purchased BioPharma Solutions' business (now known as Simtra BioPharma Solutions) from Baxter International Inc. for an undisclosed sum. Through this acquisition, Advent International and Warburg Pincus seek to bolster their position in the biopharmaceutical manufacturing industry by capitalizing on BioPharma Solutions’ specialized knowledge in contract development and manufacturing of biologics and biosimilars, thus addressing the worldwide need for cutting-edge biopharma production capacity. Baxter International Inc. is a US-based biotechnology company offering biosimilar contract manufacturing services.

Major companies operating in the biosimilar contract manufacturing market are Thermo Fisher Scientific Inc., Biocon Limited, Lonza Group AG, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Laboratorios Farmacéuticos Rovi S.A., Vetter Pharma-Fertigung GmbH & Co. KG, National Resilience Inc., Porton Pharma Solutions Co. Ltd., Syngene International Limited, Rentschler Biopharma SE, Boehringer Ingelheim International GmbH, Enzene Biosciences Ltd., Prestige Biologics Co. Ltd., Mabion S.A., HALIX B.V., BioConnection B.V., BioCina Pty Ltd, Mycenax Biotech Inc., Polpharma Biologics S.A.

North America was the largest region in the biosimilar contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilar contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilar contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the biosimilar contract manufacturing market by increasing costs of imported bioreactors, cell culture media, purification equipment, analytical instruments, and packaging systems used in biosimilar production. North America and Europe are most affected due to dependence on imported bioprocess components, while Asia-Pacific faces cost challenges in export-driven biosimilar manufacturing. These tariffs are increasing production expenses and affecting pricing competitiveness. However, they are also driving localization of manufacturing infrastructure, regional sourcing of consumables, and long-term investments in domestic biosimilar production capabilities.

The biosimilar contract manufacturing market research report is one of a series of new reports that provides biosimilar contract manufacturing market statistics, including biosimilar contract manufacturing industry global market size, regional shares, competitors with a biosimilar contract manufacturing market share, detailed biosimilar contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar contract manufacturing industry. This biosimilar contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilar contract manufacturing involves outsourcing the production of biosimilar drugs to expert third-party facilities equipped with cutting-edge infrastructure, specialized skills, and deep regulatory knowledge. These partners create biosimilars - biologic drugs that closely match approved reference biologics in safety, efficacy, and quality. This approach allows biopharmaceutical firms to cut production expenses, maintain regulatory standards, and speed up market entry.

The primary product categories in biosimilar contract manufacturing include monoclonal antibodies, insulin, erythropoietin, granulocyte colony-stimulating factor, and additional types. Monoclonal antibodies are lab-produced proteins designed with high specificity to identify and attach to a particular target (antigen) on cells or molecules, supporting accurate diagnostics or treatments. They provide services like process development, analytical and quality control, fill-and-finish operations, packaging, and more, using source systems such as mammalian and non-mammalian. Applications span oncology, autoimmune diseases, blood disorders, growth hormone deficiency, and others, with end users including pharmaceutical and biotech companies.

The biosimilar contract manufacturing market consists of revenues earned by entities by providing services such as cell line development, process optimization, upstream and downstream processing, formulation, fill-finish, quality control, packaging, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The biosimilar contract manufacturing market also includes sales of biosimilar drug substances, intermediates, active pharmaceutical ingredients (APIs), finished dosage forms, cell culture media, single-use bioreactors, chromatography resins, filtration systems, and other bioprocessing consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.